SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.
Keywords: Raynaud’s phenomenon; digital ulcers; immunosuppressive therapy; interstitial lung disease; pulmonary arterial hypertension; renal crisis; skin fibrosis; systemic sclerosis; treatment.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.